JP2023550191A5 - - Google Patents

Info

Publication number
JP2023550191A5
JP2023550191A5 JP2023531563A JP2023531563A JP2023550191A5 JP 2023550191 A5 JP2023550191 A5 JP 2023550191A5 JP 2023531563 A JP2023531563 A JP 2023531563A JP 2023531563 A JP2023531563 A JP 2023531563A JP 2023550191 A5 JP2023550191 A5 JP 2023550191A5
Authority
JP
Japan
Prior art keywords
nanocage
fusion protein
monomer
subunit
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023531563A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550191A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2021/051690 external-priority patent/WO2022109743A1/en
Publication of JP2023550191A publication Critical patent/JP2023550191A/ja
Publication of JP2023550191A5 publication Critical patent/JP2023550191A5/ja
Pending legal-status Critical Current

Links

JP2023531563A 2020-11-25 2021-11-25 Dr4および/またはdr5を標的とするポリペプチドならびに関連する組成物および方法 Pending JP2023550191A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063118306P 2020-11-25 2020-11-25
US63/118,306 2020-11-25
PCT/CA2021/051690 WO2022109743A1 (en) 2020-11-25 2021-11-25 Polypeptides targeting dr4 and/or dr5 and related compositions and methods

Publications (2)

Publication Number Publication Date
JP2023550191A JP2023550191A (ja) 2023-11-30
JP2023550191A5 true JP2023550191A5 (cg-RX-API-DMAC7.html) 2024-12-02

Family

ID=81753696

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023531563A Pending JP2023550191A (ja) 2020-11-25 2021-11-25 Dr4および/またはdr5を標的とするポリペプチドならびに関連する組成物および方法

Country Status (9)

Country Link
US (1) US20240182544A1 (cg-RX-API-DMAC7.html)
EP (1) EP4251654A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023550191A (cg-RX-API-DMAC7.html)
KR (1) KR20230116833A (cg-RX-API-DMAC7.html)
CN (1) CN116917339A (cg-RX-API-DMAC7.html)
AU (1) AU2021386892A1 (cg-RX-API-DMAC7.html)
CA (1) CA3202378A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023006148A (cg-RX-API-DMAC7.html)
WO (1) WO2022109743A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024003139A (es) * 2021-09-13 2024-06-24 Hospital For Sick Children Multabody dirigido a dr5 para el tratamiento del cancer.
WO2024050648A1 (en) * 2022-09-11 2024-03-14 Radiant Biotherapeutics Inc. Treatment of chemo-resistant tumors using multabodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX391162B (es) * 2015-10-30 2025-03-21 Galaxy Biotech Llc Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5
CA3071922A1 (en) * 2017-08-04 2019-02-07 The Governing Council Of The University Of Toronto Nanoparticle platform for antibody and vaccine delivery
KR102348838B1 (ko) * 2019-03-07 2022-01-11 경북대학교 산학협력단 트레일 트라이머와 암표적 펩타이드를 멀티디스플레이하는 페리틴 나노케이지 및 이의 항암제로서의 용도
CA3136730A1 (en) * 2019-04-25 2020-10-29 The Regents Of The University Of California Self-assembling protein nanocage decorated with antibodies (sapna) and parts thereof

Similar Documents

Publication Publication Date Title
AU2019398214B2 (en) Fusion protein constructs for complement associated disease
TWI374891B (en) Trimeric soluble antibody and the generating and using method thereof
JP6104121B2 (ja) 操作されたヘテロ二量体タンパク質ドメイン
JP2024504777A5 (cg-RX-API-DMAC7.html)
KR101522954B1 (ko) 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도
EP3356420B1 (en) Multispecific antibodies
JP6853250B2 (ja) 抗体の挿入可能な可変フラグメント及びnkg2dリガンドの改変されたa1−a2ドメイン、及び非天然のnkg2d受容体に結合する非天然のnkg2dリガンド
JP7116736B2 (ja) 操作されたヘテロ二量体タンパク質
JP7583411B2 (ja) Fc領域改変抗体の精製方法
JP2022512234A5 (cg-RX-API-DMAC7.html)
JP2023504914A5 (cg-RX-API-DMAC7.html)
JP2023544211A5 (cg-RX-API-DMAC7.html)
US20170210818A1 (en) Constant region antibody fusion proteins and compositions thereof
JP2020517287A5 (cg-RX-API-DMAC7.html)
JP2019533441A5 (cg-RX-API-DMAC7.html)
CN110234355A (zh) 单体人IgG1 Fc和双特异性抗体
JP2023553697A5 (cg-RX-API-DMAC7.html)
JP2021512159A5 (cg-RX-API-DMAC7.html)
JP2020505919A5 (cg-RX-API-DMAC7.html)
WO2023186120A1 (zh) 抗血清白蛋白纳米抗体及其衍生物
JP2025160405A (ja) 特異的結合分子
CN108473571A (zh) 结合人Fc受体的融合蛋白
JP2019505565A5 (cg-RX-API-DMAC7.html)
JPWO2022224997A5 (cg-RX-API-DMAC7.html)
CA3180251A1 (en) Cytokine conjugates